Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.40 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528811 | 0.85 | CTSD (0.44) | BACE1CTSD | |
| SCHEMBL4529247 | 0.82 | HTR2A (0.30) | — | |
| SCHEMBL4533462 | 0.79 | SRC (0.38) | CTSD | |
| SCHEMBL4524788 | 0.77 | BACE1 (0.37) | BACE1CTSD | |
| SCHEMBL4526176 | 0.76 | SRC (0.33) | CTSD | |
| SCHEMBL4524953 | 0.74 | BACE1 (0.40) | BACE1CTSD | |
| SCHEMBL4532518 | 0.73 | CNR2 (0.38) | BACE1 | |
| SCHEMBL4518695 | 0.73 | GRIA1 (0.40) | CTSDLRRK2 | |
| SCHEMBL4528908 | 0.72 | TRPA1 (0.44) | BACE1 | |
| SCHEMBL4521790 | 0.71 | BRD4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | claimed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | BACE1 3629/4885CTSD 3781/4885IDO1 460/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | BACE1 3629/4885CTSD 3781/4885IDO1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.